Sun Pharma aims to spend 7-8 percent of sales in current fiscal on RnD
According to Shanghvi, the domestic pharmaceutical market size is estimated to reach USD 35-39 billion by 2027, recording 7.5-10.5 per cent compounded annual growth.
New Delhi: Sun Pharmaceutical Industries Ltd aims to spend 7-8 per cent of its sales in the current fiscal on research and development activities as it looks to further strengthen its product portfolio across therapeutic segments, a senior company official said on Monday.Addressing shareholders during the Annual General Meeting (AGM), Managing Director Dilip Shanghvi said the company did well...
New Delhi: Sun Pharmaceutical Industries Ltd aims to spend 7-8 per cent of its sales in the current fiscal on research and development activities as it looks to further strengthen its product portfolio across therapeutic segments, a senior company official said on Monday.
Addressing shareholders during the Annual General Meeting (AGM), Managing Director Dilip Shanghvi said the company did well in all its geographies last fiscal, recording double-digit growth.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd